Hsbc Holdings PLC Sells 3,573 Shares of Stryker Corporation $SYK

Hsbc Holdings PLC cut its position in Stryker Corporation (NYSE:SYK) by 0.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 608,559 shares of the medical technology company’s stock after selling 3,573 shares during the period. Hsbc Holdings PLC’s holdings in Stryker were worth $214,056,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in SYK. Sankala Group LLC bought a new stake in shares of Stryker in the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in Stryker during the fourth quarter worth about $26,000. United Financial Planning Group LLC acquired a new position in Stryker in the third quarter valued at about $27,000. Atlas Capital Advisors Inc. acquired a new position in Stryker in the fourth quarter valued at about $27,000. Finally, DJE Kapital AG bought a new stake in shares of Stryker in the fourth quarter worth about $28,000. 77.09% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on SYK. UBS Group dropped their price target on Stryker from $400.00 to $380.00 and set a “neutral” rating on the stock in a research report on Tuesday, March 17th. Weiss Ratings cut Stryker from a “hold (c+)” rating to a “hold (c)” rating in a research note on Monday, May 4th. The Goldman Sachs Group restated a “neutral” rating and set a $361.00 target price on shares of Stryker in a report on Friday, May 1st. Needham & Company LLC cut their price target on shares of Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. Finally, Sanford C. Bernstein set a $410.00 price target on shares of Stryker in a report on Friday, May 1st. Sixteen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $395.33.

Insider Activity at Stryker

In related news, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP M Kathryn Fink sold 3,500 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $283.45, for a total value of $992,075.00. Following the sale, the vice president owned 177 shares in the company, valued at $50,170.65. The trade was a 95.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock valued at $100,659,489. 4.60% of the stock is owned by insiders.

Stryker Price Performance

Shares of SYK opened at $308.62 on Friday. The company has a quick ratio of 1.25, a current ratio of 2.11 and a debt-to-equity ratio of 0.62. Stryker Corporation has a twelve month low of $281.00 and a twelve month high of $404.87. The stock has a market capitalization of $118.31 billion, a P/E ratio of 35.72, a P/E/G ratio of 1.97 and a beta of 0.78. The company has a 50 day moving average of $313.81 and a 200-day moving average of $341.71.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a return on equity of 23.42% and a net margin of 13.20%.The business had revenue of $6.02 billion during the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the prior year, the firm earned $2.84 EPS. The business’s revenue for the quarter was up 2.6% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. As a group, equities research analysts forecast that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be issued a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.1%. Stryker’s dividend payout ratio (DPR) is presently 40.74%.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.